Accéder au contenu
Merck

Pharmacokinetics of brucine after intravenous and oral administration to rats.

Fitoterapia (2011-10-01)
Jun Chen, Han-Lu Xiao, Rong-Rong Hu, Wei Hu, Zhi-Peng Chen, Hao Cai, Xiao Liu, Tu-Lin Lu, Yun Fang, Bao-Chang Cai
RÉSUMÉ

The toxicity depending on both dose and administration route is the major obstacle to the development of brucine, a bioactive alkaloid from Semen Strychni. In this study, the apparent partition coefficient and plasma protein binding extent of brucine were determined. In addition, the dose-dependency of the pharmacokinetics of brucine was investigated. Three intravenous (2.5, 5 and 10 mg/kg) and three oral (10, 20 and 40 mg/kg) doses were administered to rats. After intravenous administration, the systemic clearance was reduced and AUC was nonlinearly increased as a function of dose. Upon oral administration, brucine was rapidly absorbed (T(max)<0.5h), which was consistent with previously reported high Caco-2 P(app) values. The increase in AUC was proportional to the increase in dose. The oral bioavailability (F) did not vary with the dose (F=40.31%, 47.15% and 43.02% for 10, 20, 40 mg/kg doses, respectively). However, the dose-proportionality was not observed with C(max). The values of C(max)/Dose were calculated to be 92.92±45.83, 55.73±24.01 and 36.29±22.44 μg/L for 10, 20 and 40 mg/kg, respectively. The results of dose-dependent pharmacokinetic behavior under different administration routes may account for the significantly different toxicities of brucine between intravenous and oral administration.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Brucine, anhydrous, 98%